Results 241 to 250 of about 128,118 (293)
Subacute myelogenous leukemia. A special type of myelogenous leukemia.
Chinese medical journal, 1982 C L, Yang +4 more
openaire +1 more source
Interferon-Based Therapeutics in Cancer Therapy: Past, Present, and Future. [PDF]
Int J Mol SciVorona K +6 more
europepmc +1 more source
Some of the next articles are maybe not open access.
Related searches:
Related searches:
Extramedullary acute myelogenous leukemia
Blood Reviews, 2016Extramedullary leukemia (EM AML), also known as myeloid sarcoma, is a rare manifestation of acute myelogenous leukemia and often accompanies bone marrow involvement. EM AML is diagnosed based on H&E stains with ancillary studies including flow cytometry and cytogenetics.
Melhem, Solh +4 more
openaire +3 more sources
Current Opinion in Oncology, 2001
Chronic myelogenous leukemia (CML) is a clonal hematopoietic stem cell disorder characterized by the (9:22) translocation and resultant production of the constitutively activated bcr-abl tyrosine kinase. Characterized clinically by marked myeloid proliferation, it invariably terminates in an acute leukemia.
M J, Mauro, B J, Druker
+8 more sources
Chronic myelogenous leukemia (CML) is a clonal hematopoietic stem cell disorder characterized by the (9:22) translocation and resultant production of the constitutively activated bcr-abl tyrosine kinase. Characterized clinically by marked myeloid proliferation, it invariably terminates in an acute leukemia.
M J, Mauro, B J, Druker
+8 more sources
Experimental Hematology, 2009
Acute myeloid leukemia (AML) is a heterogeneous disease with outcomes dependent upon several factors, including patient age, karyotype, mutational status, and comorbid conditions. For younger patients, approximately 60% to 80% achieve complete remission with standard therapy involving cytarabine and an anthracycline.
Joshua L, Shipley, James N, Butera
openaire +2 more sources
Acute myeloid leukemia (AML) is a heterogeneous disease with outcomes dependent upon several factors, including patient age, karyotype, mutational status, and comorbid conditions. For younger patients, approximately 60% to 80% achieve complete remission with standard therapy involving cytarabine and an anthracycline.
Joshua L, Shipley, James N, Butera
openaire +2 more sources
Current Opinion in Hematology, 1999
Over the past year, new information has been reported on the biology and treatment of chronic myelogenous leukemia (CML). Chronic myelogenous leukemia is characterized by the breakpoint cluster region (BCR-ABL) chimeric gene, the product of which is p210BCR-ABL, a tyrosine kinase that gives hematopoietic cells the characteristics of excessive ...
U R, Osarogiagbon, P B, McGlave
openaire +2 more sources
Over the past year, new information has been reported on the biology and treatment of chronic myelogenous leukemia (CML). Chronic myelogenous leukemia is characterized by the breakpoint cluster region (BCR-ABL) chimeric gene, the product of which is p210BCR-ABL, a tyrosine kinase that gives hematopoietic cells the characteristics of excessive ...
U R, Osarogiagbon, P B, McGlave
openaire +2 more sources
Critical Reviews in Oncology/Hematology, 1998
The incidence of acute myelogenous leukaemia (AML) increases steadily with age, more than 50% of the cases being diagnosed in subjects aged 60 years or over [1,2]. Age has been reported as an adverse prognostic indicator in AML affecting both remission rates and survival [1–3].
A, Pinto, G B, Zulian, E, Archimbaud
openaire +2 more sources
The incidence of acute myelogenous leukaemia (AML) increases steadily with age, more than 50% of the cases being diagnosed in subjects aged 60 years or over [1,2]. Age has been reported as an adverse prognostic indicator in AML affecting both remission rates and survival [1–3].
A, Pinto, G B, Zulian, E, Archimbaud
openaire +2 more sources